Fu K P, Neu H C
Antimicrob Agents Chemother. 1978 Sep;14(3):322-6. doi: 10.1128/AAC.14.3.322.
The stability to beta-lactamase hydrolysis of HR 756, a new cephalosporin antibiotic, was compared to the beta-lactamase stability of cefoxitin and cefuroxime. HR 756, cefoxitin, and cefuroxime were not hydrolyzed by Richmond type I, III, IV, and V beta-lactamases. Antibacterial activity of HR 756 correlated well with resistance to beta-lactamase hydrolysis except against Pseudomonas aeruginosa. HR 756, cefoxitin, and cefuroxime inhibited type I beta-lactamases, but not type III, IV, or V enzymes. HR 756 was the most active inhibitor.
将新型头孢菌素抗生素HR 756对β-内酰胺酶水解的稳定性与头孢西丁和头孢呋辛的β-内酰胺酶稳定性进行了比较。HR 756、头孢西丁和头孢呋辛不会被里士满I型、III型、IV型和V型β-内酰胺酶水解。HR 756的抗菌活性与对β-内酰胺酶水解的抗性密切相关,但对铜绿假单胞菌除外。HR 756、头孢西丁和头孢呋辛可抑制I型β-内酰胺酶,但不抑制III型、IV型或V型酶。HR 756是活性最强的抑制剂。